Skip to main content
Publications
Nagar SP, Fox KM, Rane PP, Beaubrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K. Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A261.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Gunda P, Graham CN, Miles L, Beard S, van Keep M. The cost-effectiveness of secukinumab versus tumour necrosis factor alpha inhibitor biosimilars for ankylosing spondylitis in the UK. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Jarmul JA, Pletcher MJ, Earnshaw S, Weinberger M, Jonas D, Avery C, Hassmiller Lich K, Wheeler S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of cardiovascular disease: a cost-effectiveness analysis. Presented at the 2017 (SGIM) Society of General Internal Medicine Annual Meeting; April 20, 2017. Washington, DC.
Kajinami K, Nagar SP, Meyers J, Rane PP, Davis K, Fox KM, Beaubrun A, Inomata H, Qian Y. Treatment utilization patterns and possible statin intolerance among high-risk patients in a real-world Japanese population. Poster presented at the 81st Annual Scientific Meeting of the Japanese Circulation Society; March 19, 2017. Kanazawa, Japan.